S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies-Reference-Cited by-同舟云学术

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Published:2018-06-28 Issue:3 Volume:119 Page:339-346
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Wagner Nikolaus B,Forschner Andrea,Leiter Ulrike,Garbe Claus,Eigentler Thomas K

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0167-x.pdf

Reference40 articles.

1. Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

2. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).

3. Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

4. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med 8, 328rv324 (2016).

5. Eton, O. et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16, 1103–1111 (1998).

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy for diagnostic and prognostic evaluation of melanoma;Frontiers in Cell and Developmental Biology;2024-08-02

2. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study;ESMO Open;2024-08

3. Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients;European Journal of Surgical Oncology;2024-07

4. Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer;Frontiers in Immunology;2024-06-07

5. Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy;Nature Communications;2024-05-08